Matthew Smith MD PhD

Oncology•Boston, MA

Genitourinary Oncology, Hematologic Oncology

Director, MGH Genitourinary Malignancies Program

Join to View Full Profile

55 Fruit StBoston, MA 02114
Phone+1 617-724-5257
Fax+1 617-726-4899

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
Duke University School of MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1994 - 2027
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 2
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy Start of enrollment: 2006 Mar 01
Completed
Phase 3
Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer Start of enrollment: 2002 Nov 01
Completed
Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer Start of enrollment: 2006 Aug 01
Completed
Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors Start of enrollment: 2007 Sep 01
Completed
Phase 2
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 1
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 Jan 20
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen ...
Marc-Oliver Grimm, Matthew Smith, Maha Hussain, Fred Saad, Karim Fizazi
European Urology. 2025-06-20
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
Neal Shore, Sarah M Nielsen, Edward D Esplin, Emmanuel S Antonarakis, Pedro C Barata
JCO Oncology Practice. 2025-06-01
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.
Kim N Chi, Elena Castro, Gert Attard, Matthew R Smith, Shahneen Sandhu
European Urology Oncology. 2025-05-05

Other

Initial hormone therapy for metastatic prostate cancer
Smith MR, Lee RJ
http://www.uptodate.com/contents/initial-hormone-therapy-for-metastatic-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-04-09
Side effects of androgen deprivation therapy
Smith MR, Crawford ED
http://www.uptodate.com/contents/side-effects-of-androgen-deprivation-therapy
UpToDate, Wolters Kluwer Health - 2013-03-27

Press Mentions

Biden’s Sudden Diagnosis of Aggressive Prostate Cancer Is Unfortunately All Too CommonMay 19th, 2025
What We Know About Joe Biden’s ‘Aggressive’ Prostate Cancer Diagnosis and Treatment OptionsMay 19th, 2025
What Doctors Say About Biden’s Prostate Cancer DiagnosisMay 19th, 2025
Join now to see all